Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 35.9% in December

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a significant decrease in short interest in December. As of December 31st, there was short interest totalling 22,500 shares, a decrease of 35.9% from the December 15th total of 35,100 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average trading volume of 49,600 shares, the short-interest ratio is presently 0.5 days.

Avenue Therapeutics Price Performance

ATXI traded down $0.15 on Thursday, reaching $1.75. The company’s stock had a trading volume of 69,234 shares, compared to its average volume of 85,473. Avenue Therapeutics has a 1 year low of $1.60 and a 1 year high of $15.00. The business’s 50 day moving average is $1.92 and its 200 day moving average is $2.41. The stock has a market cap of $3.59 million, a price-to-earnings ratio of 0.10 and a beta of -0.27.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Avenue Therapeutics stock. Armistice Capital LLC purchased a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned 7.97% of Avenue Therapeutics at the end of the most recent quarter. 17.34% of the stock is owned by institutional investors and hedge funds.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.